{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-042078","form_type":"8-K","ticker":"ABSI","cik":"0001672688","company_name":"Absci Corp","filed_at":"2023-12-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.013167+00:00","generated_at":"2026-06-07T09:52:21.842580+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Absci announces strategic R&D partnership with PrecisionLife to develop AI-enabled drug pipeline","bullets":["Partnership combines Absci's generative AI antibody design with PrecisionLife's disease biology to develop up to five drug targets.","With this partnership, Absci has signed ten new Active Programs in 2023, achieving its full-year outlook.","Collaboration aims to create a shared pipeline of novel biotherapeutics for chronic diseases with unmet medical needs.","Absci and PrecisionLife will jointly evaluate options to advance programs and share in potential value."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-042078","json":"https://secwatch.observer/filing/0001628280-23-042078.json","markdown":"https://secwatch.observer/filing/0001628280-23-042078.md","text":"https://secwatch.observer/filing/0001628280-23-042078.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1672688/000162828023042078/0001628280-23-042078-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1672688/000162828023042078/absc-20231220.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T09:52:21.842580+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}